Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis
Go back to Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis| Regeneron (NASDAQ: REGN) | Delayed: 896.82 +2.83 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $893.99 | 52 Week High | $592.36 | |||
| Open | $913.97 | 52 Week Low | $325.35 | |||
| Day High | $920.73 | P/E | 235.39 | |||
| Day Low | $891.46 | EPS | $3.81 | |||
| Volume | 507,468 | |||||
| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 30.41 +0.36 (1.20%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.05 | 52 Week High | $35.13 | |||
| Open | $30.20 | 52 Week Low | $28.10 | |||
| Day High | $30.50 | P/E | N/A | |||
| Day Low | $30.20 | EPS | $0.00 | |||
| Volume | 18,593,670 | |||||
